» Articles » PMID: 23664989

Immunogenicity of Sequences Around HIV-1 Protease Cleavage Sites: Potential Targets and Population Coverage Analysis for a HIV Vaccine Targeting Protease Cleavage Sites

Overview
Journal Vaccine
Date 2013 May 14
PMID 23664989
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Developing an effective preventative vaccine against HIV-1 has proved to be a great challenge. The classical and proven vaccine approach has failed so far or produced a modest effect, new approaches are needed. In this study we evaluated the immunogenicity of the sequences around the protease cleavage sites (PCS) and the population coverage of a vaccine targeting HIV-1 PCS. The sequence conservation was evaluated by comparing entropy score of sequences around PCS with Gag and Pol. The immunogenicity of sequences around the 12 PCS (+10/-10 amino acids) was analyzed by identifying epitopes of HLA class I alleles in PCS region using four approaches: (1) identification of previously reported HLA class I allele epitopes around PCS region; (2) screening and validating epitopes of 8 HLA class I alleles common to most world populations using iTopia Epitope Discovery system and IFN-γ ELISpot assays; (3) screening of 151 patients of Pumwani cohort for PBMC IFN-γ ELISPOT responses to the subtype A and D consensus around PCS region; and (4) prediction of HLA alleles with epitopes around the PCS using NetMHCpan. Population coverage was calculated using the web-based analysis tool of the Immune Epitope Database based on HLA class I genotype frequencies from dbMHC database. The results showed that many HLA class I alleles have multiple epitopes in the 12 PCS regions, indicating sequence immunogenicity around PCS. Multiple epitopes of many HLA class I alleles common to >95% world populations have been identified around the 12 PCS region. Targeting these sites is a feasible vaccine approach.

Citing Articles

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity.

Mandal S, Ghosh J, Lohani S, Zhao M, Cheng Y, Burrack R Emerg Microbes Infect. 2024; 13(1):2377606.

PMID: 38979723 PMC: 11259082. DOI: 10.1080/22221751.2024.2377606.


Natural Immunity against HIV-1: Progression of Understanding after Association Studies.

Luo M Viruses. 2022; 14(6).

PMID: 35746714 PMC: 9227919. DOI: 10.3390/v14061243.


Polymeric nanoparticle vaccines to combat emerging and pandemic threats.

Wibowo D, Jorritsma S, Gonzaga Z, Evert B, Chen S, Rehm B Biomaterials. 2020; 268:120597.

PMID: 33360074 PMC: 7834201. DOI: 10.1016/j.biomaterials.2020.120597.


Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.

Li H, Omange R, Liang B, Toledo N, Hai Y, Liu L J Clin Invest. 2020; 130(12):6429-6442.

PMID: 32853182 PMC: 7685735. DOI: 10.1172/JCI138728.


Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen.

Dacoba T, Omange R, Li H, Crecente-Campo J, Luo M, Alonso M ACS Nano. 2019; 13(5):4947-4959.

PMID: 30964270 PMC: 6607401. DOI: 10.1021/acsnano.8b07662.